235 related articles for article (PubMed ID: 15119908)
1. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program.
Menza M; Vreeland B; Minsky S; Gara M; Radler DR; Sakowitz M
J Clin Psychiatry; 2004 Apr; 65(4):471-7. PubMed ID: 15119908
[TBL] [Abstract][Full Text] [Related]
2. A program for managing weight gain associated with atypical antipsychotics.
Vreeland B; Minsky S; Menza M; Rigassio Radler D; Roemheld-Hamm B; Stern R
Psychiatr Serv; 2003 Aug; 54(8):1155-7. PubMed ID: 12883145
[TBL] [Abstract][Full Text] [Related]
3. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.
Kwon JS; Choi JS; Bahk WM; Yoon Kim C; Hyung Kim C; Chul Shin Y; Park BJ; Geun Oh C
J Clin Psychiatry; 2006 Apr; 67(4):547-53. PubMed ID: 16669719
[TBL] [Abstract][Full Text] [Related]
4. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
Chen CK; Chen YC; Huang YS
Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
[TBL] [Abstract][Full Text] [Related]
5. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial.
Alvarez-Jiménez M; González-Blanch C; Vázquez-Barquero JL; Pérez-Iglesias R; Martínez-García O; Pérez-Pardal T; Ramírez-Bonilla ML; Crespo-Facorro B
J Clin Psychiatry; 2006 Aug; 67(8):1253-60. PubMed ID: 16965204
[TBL] [Abstract][Full Text] [Related]
8. A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder.
Lee SJ; Choi EJ; Kwon JS
J Clin Psychiatry; 2008 Apr; 69(4):555-62. PubMed ID: 18312061
[TBL] [Abstract][Full Text] [Related]
9. Weight loss in overweight patients maintained on atypical antipsychotic agents.
Centorrino F; Wurtman JJ; Duca KA; Fellman VH; Fogarty KV; Berry JM; Guay DM; Romeling M; Kidwell J; Cincotta SL; Baldessarini RJ
Int J Obes (Lond); 2006 Jun; 30(6):1011-6. PubMed ID: 16432547
[TBL] [Abstract][Full Text] [Related]
10. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Jarskog LF; Hamer RM; Catellier DJ; Stewart DD; Lavange L; Ray N; Golden LH; Lieberman JA; Stroup TS;
Am J Psychiatry; 2013 Sep; 170(9):1032-40. PubMed ID: 23846733
[TBL] [Abstract][Full Text] [Related]
11. Reversal of antipsychotic-associated weight gain.
O'Keefe CD; Noordsy DL; Liss TB; Weiss H
J Clin Psychiatry; 2003 Aug; 64(8):907-12. PubMed ID: 12927005
[TBL] [Abstract][Full Text] [Related]
12. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
13. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
[TBL] [Abstract][Full Text] [Related]
14. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
[TBL] [Abstract][Full Text] [Related]
15. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Brar JS; Ganguli R; Pandina G; Turkoz I; Berry S; Mahmoud R
J Clin Psychiatry; 2005 Feb; 66(2):205-12. PubMed ID: 15705006
[TBL] [Abstract][Full Text] [Related]
16. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
de Silva VA; Dayabandara M; Wijesundara H; Henegama T; Gunewardena H; Suraweera C; Hanwella R
J Psychopharmacol; 2015 Dec; 29(12):1255-61. PubMed ID: 26510448
[TBL] [Abstract][Full Text] [Related]
17. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
Ball MP; Warren KR; Feldman S; McMahon RP; Kelly DL; Buchanan RW
Clin Schizophr Relat Psychoses; 2011 Apr; 5(1):17-25. PubMed ID: 21459735
[TBL] [Abstract][Full Text] [Related]
18. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
19. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics.
Weber M; Wyne K
Schizophr Res; 2006 Mar; 83(1):95-101. PubMed ID: 16507343
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
